Clinical Focus

  • Nuclear Medicine

Academic Appointments

Administrative Appointments

  • Director of Pediatric Nuclear Medicine, Lucile Packard Children's Hospital (2018 - Present)

Professional Education

  • Board Certification: Diagnostic Radiology, American Board of Radiology (1983)
  • Board Certification: Nuclear Medicine, Royal College of Physicians and Surgeons of Canada
  • Board Certification: Diagnostic Radiology, Royal College of Physicians and Surgeons of Canada
  • Board Certification: Pediatric Radiology, American Board of Radiology (2001)
  • Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (1989)
  • Fellowship:University of British Columbia (1989) BCCanada
  • Fellowship:Hospital For Sick Children (1983) Canada
  • Residency:University of Toronto (1981)
  • Internship:Toronto General Hospital (1978) Canada
  • Medical Education:University of Manitoba Office of the Registrar (1977) Canada


All Publications

  • American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Body. Journal of nuclear medicine Subramaniam, R. M., Jadvar, H., Colletti, P. M., Guimaraes, A., Gullapali, R., Iagaru, A. H., McConathy, J., Meltzer, C. C., Nadel, H., Noto, R. B., Packard, A. B., Rohren, E., Oates, M. E. 2017


    This joint statement is intended to guide credentialing bodies that privilege physicians to oversee the performance of and participation in the interpretation of PET/MR imaging in adult and pediatric patients in the United States.

    View details for DOI 10.2967/jnumed.117.193524

    View details for PubMedID 28473601

  • Response Assessment Criteria and Their Applications in Lymphoma: Part 2 JOURNAL OF NUCLEAR MEDICINE Moghbel, M. C., Mittra, E., Gallamini, A., Niederkohr, R., Chen, D. L., Zukotynski, K., Nadel, H., Kostakoglu, L. 2017; 58 (1): 13-22


    Interim and end-of-treatment PET/CT have become central to the evaluation of Hodgkin and non-Hodgkin lymphoma. This review article seeks to aid clinical decision making by providing an overview of available data on the diagnostic and prognostic value of PET/CT imaging for response assessment and pretransplant evaluation in lymphoma. The relative strengths and limitations of these techniques in various disease subtypes and clinical scenarios are explored, along with their current standards for reporting and latest developments. Particular attention is given to response-adapted therapy, which is emerging as a cornerstone of clinical management.

    View details for DOI 10.2967/jnumed.116.184242

    View details for Web of Science ID 000391343400012

    View details for PubMedID 27879369

  • Response Assessment Criteria and Their Applications in Lymphoma: Part 1 JOURNAL OF NUCLEAR MEDICINE Moghbel, M. C., Kostakoglu, L., Zukotynski, K., Chen, D. L., Nadel, H., Niederkohr, R., Mittra, E. 2016; 57 (6): 928-935


    The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.

    View details for DOI 10.2967/jnumed.115.166280

    View details for Web of Science ID 000377052400045

    View details for PubMedID 27127227

  • Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee PEDIATRIC BLOOD & CANCER Meyer, J. S., Nadel, H. R., Marina, N., Womer, R. B., Brown, K. L., Eary, J. F., Gorlick, R., Grier, H. E., Randall, R. L., Lawlor, E. R., Lessnick, S. L., Schomberg, P. J., Kailo, M. D. 2008; 51 (2): 163-170


    The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standardized regimen of imaging examinations performed prior to, during, and following therapy. This article presents imaging guidelines developed by a multidisciplinary group from the COG Bone Tumor Committee. These guidelines provide both required and recommended studies. Recommended examinations may become required in the future. These guidelines should be considered a work in progress that will evolve with advances in imaging and childhood cancer research.

    View details for DOI 10.1002/pbc.21596

    View details for Web of Science ID 000256871800004

    View details for PubMedID 18454470

Footer Links:

Stanford Medicine Resources: